Refining ARVC Risk Stratification: Does Left Ventricular Late Gadolinium Enhancement Add Incremental Value to Clinical Risk Calculators?

Refining ARVC Risk Stratification: Does Left Ventricular Late Gadolinium Enhancement Add Incremental Value to Clinical Risk Calculators?

A multi-center study of 385 ARVC patients reveals that while Left Ventricular Late Gadolinium Enhancement (LV LGE) correlates with ventricular arrhythmias, it fails to provide incremental prognostic value beyond the established ARVC risk calculator, reinforcing the calculator's role as the primary tool for clinical decision-making.
Superior Long-Term Hemodynamics with Self-Expanding Valves in Small Failed Bioprostheses: 3-Year Insights from the LYTEN Trial

Superior Long-Term Hemodynamics with Self-Expanding Valves in Small Failed Bioprostheses: 3-Year Insights from the LYTEN Trial

The 3-year analysis of the LYTEN trial reveals that self-expanding valves (SEV) significantly outperform balloon-expandable valves (BEV) in hemodynamic metrics for valve-in-valve TAVR in patients with small surgical bioprostheses, although clinical outcomes and quality of life improvements remain comparable.
ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

Recent research reveals that the common ALDH2 rs671 genetic variant significantly enhances platelet activation and arterial thrombosis through aldehyde accumulation, reactive oxygen species, and ACAD10-mediated mitophagy, identifying ALDH2 as a potential novel target for personalized antiplatelet strategies in East Asian patients.